A Sequential Safety and Biomarker Study of BRAF-MEK Inhibition on the Immune Response in the Context of Combined CTLA-4 Blockade and PD-1 Blockade for BRAF Mutant Melanoma

Trial Profile

A Sequential Safety and Biomarker Study of BRAF-MEK Inhibition on the Immune Response in the Context of Combined CTLA-4 Blockade and PD-1 Blockade for BRAF Mutant Melanoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 May 2017

At a glance

  • Drugs Dabrafenib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Trametinib (Primary)
  • Indications Malignant melanoma; Skin cancer
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 11 May 2017 Status changed from suspended to recruiting.
    • 11 May 2017 Status changed from suspended to recruiting.
    • 14 Mar 2017 Status changed from recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top